<DOC>
	<DOCNO>NCT00509704</DOCNO>
	<brief_summary>The purpose study assess effect Sunitinib tumor vascularization necrosis patient metastatic renal cell cancer .</brief_summary>
	<brief_title>Influence Sutent Tumor Vascularization Necrosis Patients With Renal Cell Carcinoma</brief_title>
	<detailed_description>Sutent angiogenesis inhibitor use treatment renal cell cancer . Very often tumor necrosis see start treatment . It unknown many day effect start . In patient renal cell cancer metastasis , treat Sutent , 3 MRIs make . Kep , R2* , b-coefficient ( perfusion , hypoxia , blood volume necrosis ) measure .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>patient metastatic renal cell cancer treatment Sunitinib plan histologically verify stage IV renal cell carcinoma clear cell type measurable primary tumor metastasis ( minimal diameter 2 cm ) sit lung Karnofsky score &gt; 70 % age &gt; 18 year . write informed consent contraindication MRI contraindication treatment Sunitinib previous systemic treatment within last 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Sutent</keyword>
	<keyword>tumor necrosis</keyword>
	<keyword>DCE-MRI ( Dynamic enhance magnetic resonance imaging )</keyword>
</DOC>